XML 57 R46.htm IDEA: XBRL DOCUMENT
v3.25.1

Collaborative Agreements (Details) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 Months Ended | 3 Months Ended | 11 Months Ended | 12 Months Ended |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Jun. 18, 2024 USD ($) | May 23, 2024 USD ($) $ / shares shares | May 14, 2024 USD ($) $ / shares shares | May 08, 2024 USD ($) $ / shares shares | Apr. 16, 2024 USD ($) $ / shares shares | Mar. 25, 2024 USD ($) $ / shares shares | Jun. 10, 2022 USD ($) | Aug. 05, 2019 USD ($) shares | Jun. 30, 2019 USD ($) shares | Dec. 24, 2018 USD ($) $ / shares shares | Sep. 30, 2018 USD ($) | Dec. 31, 2017 USD ($) | Sep. 25, 2017 USD ($) | Aug. 15, 2017 USD ($) | Aug. 31, 2016 USD ($) | Aug. 31, 2016 TWD ($) | Mar. 31, 2025 USD ($) $ / shares shares | Dec. 31, 2015 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2015 TWD ($) | Dec. 31, 2024 USD ($) | Mar. 31, 2024 USD ($) | Aug. 14, 2023 $ / shares | Jul. 27, 2021 USD ($)
Collaborative Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty percentage |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 12.00% |  |  |  |  |  |
Total cash (in New Dollars) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 50,000,000,000,000 |  |  |  |
Cash equivalent |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,600,000 |  |  |  |  |  |
Additional paid-in capital |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 77,004,201 |  |
Price per share (in Dollars per share) | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1.87 |  |  |  |  |  | $ 20 |
Equity method long term investment (in Shares) | shares |  |  |  |  |  |  |  |  |  | 1,530,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Service agreement eligibility amount |  |  |  |  |  |  | $ 3,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone regulatory payment amount period |  |  |  |  |  |  | 3 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loan amount |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 249,975
Percentage of working capital convertible loan |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5.00% |  |  |  |  |  |  |
Fixed conversion price equal (in Dollars per share) | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1 |  |  |  |  |  |  |
Licensing fee |  |  |  |  |  | $ 33,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,895,556 |  |  |  |  |
FEYE stock (in Dollars per share) | $ / shares |  |  |  |  |  | $ 6 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone regulatory payment amount | $ 3,500,000 |  |  |  |  | $ 3,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of royalties of net sales |  |  |  |  |  | 5.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Recognized revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 296,000 |  |  |
Recognized revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 200,000 |  |  |  |  |  |  |
Number of shares received (in Shares) | shares |  | 1.25 | 1,250,000 | 1,250,000 |  |  |  |  |  |  |  |  |  |  |  |  | 1,250,000 |  |  |  |  |  |  |
BHK Co-Development Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Description of collaborative agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | On July 27, 2016, BioLite Taiwan and BHK agreed to amend the payment terms of the milestone payment in an aggregate amount of $10 million based on the following schedule: ● Upon the signing of the BHK Co-Development Agreement: $1 million, or 10% of total payment ● Upon the first Investigational New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or 10% of total payment ● At the completion of first phase II clinical trial: $1 million, or 10% of total payment ● At the initiation of phase III of clinical trial research: $3 million, or 30% of total payment ● Upon the New Drug Application (NDA) submission: $4 million, or 40% of total payment |  |  |  |  |  |  |
Non-refundable upfront cash payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,000,000 |  |  |  |  |  |
Data and development percentage |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10.00% |  |  |  |  |  |
Total cash amount |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,000,000 |  |  | $ 10,000,000 |  |  |  |  |  |
Licensing rights |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 31,649,000 |  |  |  |  |  |  |  |
Co-Dev Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Data and development percentage |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 50.00% |  |  |  |  |  |  |
Cash amount |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 3,000,000 |  |  |  |  |  |  |  |  |  |
Addition cash payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 3,000,000 |  |  |  |  |  |  |
Additional paid-in capital |  |  |  |  |  |  |  |  |  |  |  | $ 3,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Cash received |  |  |  |  |  |  |  |  |  |  |  | 450,000 |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Data and development percentage |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 50.00% |  |  |  |  |  |  |
Total cash amount |  |  |  |  |  |  |  |  |  |  | $ 3,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Licensing rights |  |  |  |  |  |  |  |  |  |  |  |  | $ 3,000,000 |  |  |  |  |  |  |  |  |  |  |
Cash amount |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 3,000,000 |  |  |  |  |  |  |
Research and development expense |  |  |  |  |  |  |  |  |  |  |  | $ 3,000,000 |  |  |  |  |  |  |  |  |  |  |  |
BioFirst Corporation Purchase Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares issued (in Shares) | shares |  |  |  |  |  |  |  | 41,470 | 42,857 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock consideration |  |  |  |  |  |  |  | $ 2,902,911 | $ 3,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ForSeeCon Eye Corporation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Licensing agreement | $ 100,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
BioLite Taiwan [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total cash (in New Dollars) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 50,000,000,000,000 |  |  |  |
Cash equivalent |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,600,000 |  |  |  |  |  |
Net sales profit, percentage |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 50.00% |  |  |  |
Collaborative agreement with ForSeeCon Eye Corporation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment |  |  |  |  |  | $ 30,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares paid (in Shares) | shares |  |  |  |  |  | 5,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares received (in Shares) | shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5,000,000 |  |  |  |  |  |  |
OncoX BiopPharma, Inc [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty percentage |  | 5.00% | 5.00% | 5.00% | 5.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Price per share (in Dollars per share) | $ / shares |  | $ 5 | $ 5 | $ 5 | $ 5 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares issued (in Shares) | shares |  | 1,250,000 | 1,250,000 | 1,250,000 | 1,250,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consideration paid |  | $ 6,250,000 | $ 6,250,000 | $ 6,250,000 | $ 6,250,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional milestone payment in cash |  | $ 625,000 | $ 625,000 | $ 625,000 | $ 625,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of develop and commercialize |  | 50.00% | 50.00% | 50.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Licensing fees |  | $ 100,000 | $ 100,000 | $ 100,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Rgene Corporation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Value of new shares issued |  |  |  |  |  |  |  |  |  | $ 2,550,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of note fully converted |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 37.00% |  |  |  | 26.65% |  |  |
Loan amount |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,000,000 |  |  |  |  |  |  |
Convertible loan |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 500,000 |  |  |  |  |  |  |
Rgene Corporation [Member] | Co-Dev Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of note fully converted |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6.40% |  |  |  |  |  |  |
Rgene Corporation [Member] | Service Agreements [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of note fully converted |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 26.65% |  |  |  |  |  |  |
Common Stock [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Price per share (in Dollars per share) | $ / shares |  |  |  |  |  |  |  |  |  | $ 50 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common Stock [Member] | YuanGene Corporation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Price per share (in Dollars per share) | $ / shares |  |  |  |  |  |  |  |  |  | $ 1.6 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common Stock [Member] | Rgene Studies [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of note fully converted |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 20.00% |  |  |  |  |  |  |

X
- Definition The amount of addition cash payment. + References No definition available. + Details
Name: | abvc_AdditionCashPayment
Namespace Prefix: | abvc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Additional milestone payment in cash. + References No definition available. + Details
Name: | abvc_AdditionalMilestonePaymentInCash
Namespace Prefix: | abvc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Consideration paid. + References No definition available. + Details
Name: | abvc_ConsiderationPaidForAgreement
Namespace Prefix: | abvc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Equity method long term investment. + References No definition available. + Details
Name: | abvc_EquityMethodLongTermInvestment
Namespace Prefix: | abvc_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition The value of Common stock newly issued. for example : newly issued shares means any common shares issued pursuant to the primary share purchases. + References No definition available. + Details
Name: | abvc_IssuanceOfStockValue
Namespace Prefix: | abvc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of licensing Agreement. + References No definition available. + Details
Name: | abvc_LicensingAgreement
Namespace Prefix: | abvc_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount licensing fee. + References No definition available. + Details
Name: | abvc_LicensingFees
Namespace Prefix: | abvc_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone payments royalty percentage. + References No definition available. + Details
Name: | abvc_MilestonePaymentsRoyaltyPercentage
Namespace Prefix: | abvc_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represent the amount of milestone regulatory payment. + References No definition available. + Details
Name: | abvc_MilestoneRegulatoryPaymentAmount
Namespace Prefix: | abvc_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone Regulatory Payment Amount Period. + References No definition available. + Details
Name: | abvc_MilestoneRegulatoryPaymentAmountPeriod
Namespace Prefix: | abvc_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of net sales profit. + References No definition available. + Details
Name: | abvc_NetSalesProfitPercentage
Namespace Prefix: | abvc_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Non-refundable upfront cash payment. + References No definition available. + Details
Name: | abvc_NonrefundableUpfrontCashPayment
Namespace Prefix: | abvc_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The number of shares received. + References No definition available. + Details
Name: | abvc_NumberOfSharesReceived
Namespace Prefix: | abvc_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Rate of develop and commercialize. + References No definition available. + Details
Name: | abvc_PercentageOfDevelopAndCommercialize
Namespace Prefix: | abvc_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of payments under co-development agreement. + References No definition available. + Details
Name: | abvc_PercentageOfPaymentsUnderCodevelopmentAgreement
Namespace Prefix: | abvc_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares received. + References No definition available. + Details
Name: | abvc_ReceivedShares
Namespace Prefix: | abvc_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of Royalties. + References No definition available. + Details
Name: | abvc_RoyaltiesPercentage
Namespace Prefix: | abvc_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Service agreement eligibility amount. + References No definition available. + Details
Name: | abvc_ServiceAgreementEligibilityAmount
Namespace Prefix: | abvc_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Percentage of working capital convertible loan. + References No definition available. + Details
Name: | abvc_WorkingCapitalConvertibleLoanPercentage
Namespace Prefix: | abvc_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_AdditionalPaidInCapitalCommonStock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of increase (decrease) in value of asset in contingent consideration arrangement in business combination. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 605 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 605 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 45 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21 Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 210 -Topic 946 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20 + Details
Name: | us-gaap_Cash
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_CashEquivalentsAtCarryingValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiabilityNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details
Name: | us-gaap_ConvertibleDebt
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6 + Details
Name: | us-gaap_CostOfGoodsAndServicesSold
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of revenue recognized that was previously reported as deferred or unearned revenue. + References No definition available. + Details
Name: | us-gaap_DeferredRevenueRevenueRecognized1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details
Name: | us-gaap_LoansPayable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Discloses the nature of achievements or target goals that are to be reached by specified dates to maintain the arrangement or extend it, generally without adjustment of the present financial terms of the arrangement. + References No definition available. + Details
Name: | us-gaap_LongTermPurchaseCommitmentMilestones
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of other research and development expense. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 + Details
Name: | us-gaap_OtherResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Cash payments related to participation costs. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 926 -SubTopic 230 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477628/926-230-45-1 + Details
Name: | us-gaap_PaymentsForParticipationLiabilities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Per share conversion price of preferred stock. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details
Name: | us-gaap_PreferredStockConvertibleConversionPrice
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of income earned, after hedging basis adjustments, from fees charged for prepayment of certain Federal Home Loan Bank (FHLBank) advances before original maturity. + References No definition available. + Details
Name: | us-gaap_PrepaymentFeesOnAdvancesNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details
Name: | us-gaap_SharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Per share or per unit amount of equity securities issued. + References No definition available. + Details
Name: | us-gaap_SharesIssuedPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of shares issued during the period as a result of a stock split. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesStockSplits
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details
Name: | us-gaap_StockIssuedDuringPeriodValueNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of tax expense, excluding income, excise, production and property taxes, and licenses and fees not related to production. + References No definition available. + Details
Name: | us-gaap_TaxesAndLicenses
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=abvc_BHKCoDevelopmentAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=abvc_CodevelopmentagreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=abvc_BioFirstStockPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=abvc_ForSeeConEyeCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=abvc_BioLiteTaiwanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=abvc_CollaborativeAgreementWithForSeeConEyeCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=abvc_OncoXBiopPharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_RgeneCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ServiceAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=abvc_YuanGeneCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abvc_RgeneStudiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |